NCT00608803View on ClinicalTrials.gov

Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Advanced Cancer
Interventions
DRUG

ZIO-201-T and doxorubicin

ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.

Trial Locations (2)

77024

Houston

90403

Santa Monica

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY

NCT00608803 - Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | Biotech Hunter | Biotech Hunter